Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy.

Cancer prevention research (Philadelphia, Pa.) - 1 Jun 2011

Kim Edward S, Lee J Jack, Wistuba Ignacio I

Abstract excerpt

Lung cancer has limited effective therapy and no effective prevention. Cytotoxic chemotherapy has not improved when combined with the epidermal growth factor receptor (EGFR) inhibitor erlotinib (standard lung cancer therapy) or with the rexinoid bexarotene. Combining erlotinib and bexarotene, however, to cotarget cyclin D1 via the retinoid X receptor and EGFR was active preclinically in KRAS-driven lung cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cyclin D1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Treatment Outcome

Source

Identifiers

PMID: 21636543
DOI: 10.1158/1940-6207.CAPR-11-0143

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy.PMID 21636543Read ↗

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.Semantic proximity Read ↗

Lung cancer: current therapies and new targeted treatments.Semantic proximity Read ↗

Prevention of lung cancer. The new millennium.Semantic proximity Read ↗

The Rexinoid V-125 Reduces Tumor Growth in Preclinical Models of Breast and Lung CancerSemantic proximity Read ↗

Cyclin E Transgenic Mice: Discovery Tools for Lung Cancer Biology, Therapy, and PreventionSemantic proximity Read ↗

Targeted therapies: LUX-Lung trials-not all mutations are created equal.Semantic proximity Read ↗

Cancer InterceptionSemantic proximity Read ↗

Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Lung cancer. Dacomitinib: getting on target after negative ARCHER trial.Semantic proximity Read ↗

Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.Semantic proximity Read ↗

Putting lung cancer clinical trials into perspective.Semantic proximity Read ↗

Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.